GlassScriptPhysician profile
Pratik H Thaker
NPI 1174054894
$6,970.76
in general payments reported to CMS, 2019-2025
39 companies · $2,495 in 2025
The $2,495 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $415 · 2022: $661 · 2023: $1,172 · 2024: $2,228 · 2025: $2,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,894.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $824.16 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $779.06 | 2022-2025 | |
| Amgen INC. | $711.78 | 2023-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $452.43 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $436.97 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $399.72 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Paratek Pharmaceuticals, INC. | $266.38 | 2021-2025 | Nuzyra |
| Glaxosmithkline, LLC. | $240.91 | 2021-2025 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $212.69 | 2022 | |
| Idorsia Pharmaceuticals US INC | $200.95 | 2022-2023 | Quviviq |
| Inspire Medical Systems, INC. | $175.83 | 2024-2025 | Inspire |
| Abbott Laboratories | $169.80 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Otsuka America Pharmaceutical, INC. | $167.36 | 2023-2024 | Rexulti |
| Gilead Sciences, INC. | $163.40 | 2025 | |
| Astellas Pharma US INC | $155.92 | 2023-2025 | Veozah |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $155.46 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.49 | 2021-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $129.77 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $119.12 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $108.85 | 2024-2025 | |
| Mylan Specialty L.P. | $108.78 | 2023-2024 | Yupelri |
| Viiv Healthcare Company | $94.01 | 2024-2025 | Apretude |
| Novartis Pharmaceuticals Corporation | $88.25 | 2023-2025 | |
| Corium, LLC | $84.78 | 2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.18 | 2022-2025 | Jardiance |
| Supernus Pharmaceuticals, INC. | $72.68 | 2023-2025 | Qelbree, Qelbree |
| Dynavax Technologies Corporation | $70.53 | 2023-2025 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.79 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $44.71 | 2021 | |
| Merck Sharp & Dohme LLC | $40.16 | 2021-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Dexcom, INC. | $39.77 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $36.56 | 2025 | Gemtesa |
| Edwards Lifesciences Corporation | $29.76 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sanofi Pasteur INC. | $21.21 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $19.77 | 2025 | Uptravi, Opsumit |
| Upsher-Smith Laboratories LLC | $16.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.55 | 2022 | |
| Neos Therapeutics, LP | $14.56 | 2025 | Adzenys Xr-Odt |
| Medicure Pharma INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratik Thaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.